In this work, we explored PD-L1-CAR T-cell therapy as an alternative treatment approach for NSCLC with PD-L1high and EGFR mutant phenotypes (for example, PD-L1 expression assessed to be ≥50% tumor proportion score). The gene discussed is EGFR; the disease is neoplasm.